Moderna and Merck mRNA Cancer Vaccine Cuts Melanoma Recurrence

Moderna and Merck's mRNA-based cancer vaccine Intismeran has shown it can meaningfully reduce the recurrence and spread of melanoma in late-stage clinical trials. The results mark a significant step toward personalised cancer treatment using the same mRNA platform pioneered by COVID-19 vaccines.